Search | Clinical Trials Finder

Conditions: Anemia
Interventions: Iron (ferrous sulfate); Drug
Lead sponsor: Emory University; Other
Eligibility: Up to 2 Months
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: ADHD, Iron-deficiency, Restless Legs Syndrome, Periodic Limb Movement Sleep Disorder
Interventions: ferrous sulfate; Dietary Supplement
Lead sponsor: Hugo W. Moser Research Institute at Kennedy Krieger, Inc.; Other
Eligibility: 5 Years to 18 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Anemia, Iron-Deficiency, Kidney Failure, Chronic
Interventions: Sodium Ferric Gluconate Complex in Sucrose Injection, Ferrous sulfate tablets; Drug
Lead sponsor: Watson Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 23
States / cities: Tucson, Arizona • Los Angeles, California • Palo Alto, California + 20 more

Conditions: Anemia, Iron Deficiency, Uterine Bleeding
Interventions: Ferric Derisomaltose 1000 Mg in 10 mL INTRAVENOUS SOLUTION [Monoferric], Ferrous Sulfate 65 mg elemental iron (325 mg tablets); Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Anemia
Interventions: Sodium ferric gluconate, ferrous sulfate, standard of care; Drug
Lead sponsor: Watson Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 32
States / cities: Bakersfield, California • Chula Vista, California • Long Beach, California + 29 more

Conditions: Prematurity, Iron-deficiency, Iron Deficiency Anemia, Iron Malabsorption
Interventions: Darbepoetin Alfa, Low Molecular Weight Iron Dextran, Ferumoxytol injection, Oral iron supplements; Drug
Lead sponsor: University of Washington; Other
Eligibility: Up to 3 Days
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Healthy
Interventions: AKB-6548 tablet, reference formulation given in the fasted state, AKB-6548 tablet, test formulation given in the fasted state., AKB-6548 tablet, test formulation given in the fed state; Drug
Lead sponsor: Akebia Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Kalamazoo, Michigan

Conditions: Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF), Heart Failure With Preserved Ejection Fraction (HFPEF), Iron Deficiency, Iron-deficiency Anemia (IDA)
Interventions: Ferric Carboxymaltose, Ferrous Sulfate; Drug
Lead sponsor: Syed Hamza Mufarrih; Other
Eligibility: 18 Years to 100 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Bowling Green, Kentucky

Conditions: Iron Deficiency Anemia
Interventions: Ferric carboxymaltose, Ferrous Sulfate; Drug
Lead sponsor: American Regent, Inc.; Industry
Eligibility: 1 Year to 17 Years
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 16
States / cities: Little Rock, Arkansas • Doral, Florida • Miami, Florida + 10 more

Conditions: Chronic Kidney Insufficiency, Chronic Kidney Diseases
Interventions: Ferrous Sulfate; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 1 Year to 21 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 2
States / cities: New York, New York • Philadelphia, Pennsylvania

Conditions: Anemia, Iron Deficiency (Without Anemia), Iron Absorption
Interventions: marine-based heme iron; Dietary Supplement
Lead sponsor: Nutraceuticals Research Institute; Other
Eligibility: 21 Years to 42 Years · Female only
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Huntsville, Alabama

Conditions: Iron Deficiency Anemia, Heavy Menstrual Bleeding, Abnormal Uterine Bleeding
Interventions: Ferrous sulfate; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 9 Years to 22 Years · Female only
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Iron Deficiency Anemia
Interventions: Ferric Carboxymaltose (FCM), Ferrous Sulfate Tablets, IV Iron (standard of care); Drug
Lead sponsor: American Regent, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 997 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Norristown, Pennsylvania

Conditions: Iron Deficiency Anemia
Interventions: Ferumoxytol, Saline, Ferrous sulfate tablets, Vitamin C; Drug
Lead sponsor: Auerbach Hematology Oncology Associates P C; Other
Eligibility: 18 Years and older
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Anemia
Interventions: Venofer, Ferrous Sulfate; Drug
Lead sponsor: American Regent, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Valley Forge, Pennsylvania

Conditions: Iron-refractory, Iron-deficiency Anemia (IRIDA)
Interventions: Triferic, Fer-In-Sol, Shohl's solution; Drug
Lead sponsor: Rockwell Medical Technologies, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Kalamazoo, Michigan

Conditions: Anemia
Interventions: Oral Iron, sodium ferric gluconate; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 8
States / cities: Hot Springs, Arkansas • Orange County, California • Simi Valley, California + 5 more

Conditions: Anemia
Interventions: Oral iron tablets, VIT-45; Drug
Lead sponsor: American Regent, Inc.; Industry
Eligibility: Female only
Enrollment: 361 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Norristown, Pennsylvania

Conditions: Iron Deficiency Anemia
Interventions: Sodium Ferric Gluconate Complex, Oral Iron; Drug
Lead sponsor: Watson Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 19
States / cities: Birmingham, Alabama • Mesa, Arizona • Los Angeles, California + 16 more

Conditions: Anemia, Iron-Deficiency, Kidney Failure, Chronic
Interventions: Sodium Ferric Gluconate complex in sucrose, Ferrous sulfate tablets; Drug
Lead sponsor: Watson Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 23
States / cities: Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 20 more

Conditions: Non-anemic Iron Deficiency
Interventions: Ferrous sulfate, Prenatal, Docusate Sodium, Ascorbic Acid 500Mg Tab, Placebo; Drug
Lead sponsor: Stony Brook University; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 3
States / cities: Bohemia, New York • Commack, New York • East Setauket, New York

Conditions: Iron Deficiency Anemia
Interventions: Ferrous Sulfate Oral Product; Drug
Lead sponsor: AdventHealth; Other
Eligibility: 29 Weeks to 33 Weeks
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Anemia
Interventions: Ferrous Sulfate tablets, Ferric Carboxymaltose (FCM); Drug
Lead sponsor: American Regent, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Norristown, Pennsylvania

Conditions: Malignant Neoplasms of Mesothelial and Soft Tissue, Gastrointestinal Stromal Tumor With Neurogenic Differentiation
Interventions: Ferric Carboxymaltose, Iron Supplements, Questionnaire; Drug · Dietary Supplement · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

Iron Prophylaxis for Anemia in Infants With Cyanotic Congenital Heart Disease

Impact of Iron Supplementation Treatment on Brain Iron Concentrations

Effect of Ferrlecit® Versus Oral Iron on Iron Deficient Chronic Kidney Disease (CKD) Patients

IV Iron Trial for Anemia Related to Uterine Bleeding in Female Patients Presenting to the Emergency Department

Effect of Iron Therapy as an Adjunct to Epoetin Alfa in the Anemia of Cancer Chemotherapy

Darbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm Infants

Relative Bioavailability of Two Formulations of AKB-6548 and the Food Effect of a New Tablet in Healthy Adult Subjects

IRONICA: IRON Repletion In Heart Failure - A Comparison of Oral and IV Approaches

Multicenter Randomized Active-controlled Study to Investigate Efficacy & Safety of IV FCM in Pediatric Patients With IDA

Oral Iron in Children With Chronic Kidney Disease

The Immediate and Long-term Effects of a Novel Marine-based Iron Supplement in Adult Females

Alternate Day Versus Daily Oral Iron Therapy in Adolescents

Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia (IDA)

Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient

Comparison of Safety and Efficacy of Intravenous Iron Versus Oral Iron in Chronic Renal Failure Subjects With Anemia

Pharmacokinetics and Absolute Bioavailability of Fer-In-Sol and Triferic Administered Orally With Shohl's Solution in Healthy Volunteers

Study of the Efficacy and Safety of Ferrlecit in the Maintenance Dosing in Hemodialysis Patients.

Comparison of the Safety and Efficacy of Intravenous Iron Versus Oral Iron in Subjects Who Display Postpartum Anemia

2 Doses of Ferrlecit Versus Oral Iron to Treat Iron-deficiency Anemia in Peritoneal Dialysis Patients.

Effect of Ferrlecit® Versus Oral Iron on Iron Deficient Chronic Kidney Disease (CKD) Patients Receiving Erythropoietic Agents

Treatment of Non-Anemic Iron Deficiency in Pregnancy

Donor Breast Milk 2

VIT45 Versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease

Efficacy of Ferric Carboxymaltose in Gastrointestinal Stromal Tumor (GIST) Patients With Iron Deficiency Anemia (IDA) Receiving Systemic Therapy